<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-05T17:54:03Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/27536" metadataPrefix="rdf">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/27536</identifier><datestamp>2026-02-03T12:27:56Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37959</setSpec></header><metadata><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:riuma.uma.es:10630/27536">
      <dc:title>Antioxidant and neuroprotective actions of IGF-II against glucocorticoid-induced  toxicity in dopaminergic neurons.</dc:title>
      <dc:creator>Claros-Gil, Silvia</dc:creator>
      <dc:creator>Valverde Moreno, Nadia</dc:creator>
      <dc:creator>Zamorano-González, Pablo</dc:creator>
      <dc:creator>Romero-Zerbo, Silvana Yanina</dc:creator>
      <dc:creator>Lara Fernández, Estrella</dc:creator>
      <dc:creator>Boraldi, Federica</dc:creator>
      <dc:creator>Pavía-Molina, José</dc:creator>
      <dc:creator>García-Fernández, María Inmaculada</dc:creator>
      <dc:creator>Gago-Calderón, Belén</dc:creator>
      <dc:creator>Martín-Montañez, Elisa</dc:creator>
      <dc:subject>Cerebro - Envejecimiento</dc:subject>
      <dc:subject>Parkinson, Enfermedad de</dc:subject>
      <dc:subject>Hormonas peptídicas</dc:subject>
      <dc:description>The neurodegenerative Parkinson’s disease (PD) affects 1–3% of the population aged over 65. A wide range of pathways and mechanisms are involved in its pathogenesis, such as oxidative stress, mitochondrial dysfunction, inflammation and neuronal glucocorticoid-induced toxicity, which ultimately produce a progressive loss of nigral dopamine neurons. Insulin-like growth factor II (IGF-II) has shown antioxidant and neuroprotective effects in some neurodegenerative disorders. Therefore, our aim was to study IGF-II protective effects against oxidative damage on a cellular combined model of PD and mild to moderate stress, based on corticosterone (CORT), an endocrine response marker to stress, and the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+). The dopaminergic neuronal cell line SN4741 (RRID:CVCL_S466) derived from mouse substantia nigra were exposed to 200 μM MPP+, 0.5 μM CORT or both, with or without 25 ng/mL IGF-II, for 2.5 or 6 h. Cell viability, oxidative stress parameters, mitochondrial and dopamine markers and intracellular signaling pathways were evaluated. The administration of MPP+ or CORT individually led to cell damage compared to control situations, whereas the combination of both drugs produced very considerable toxic synergistic effect. IGF-II counteracts the mitochondrial-oxidative damage, protecting dopaminergic neurons from death and neurodegeneration. IGF-II maintained the tyrosine hydroxylase expression and promotes nuclear factor (erythroid-derived 2)-like 2 antioxidant response in a glucocorticoid receptor-dependent pathway, preventing oxidative cell damage and maintaining mitochondrial function. This work revealed the potential neuroprotective role of IGF-II to protect nigral dopamine neurons against mitochondrial-oxidative damage induced by CORT and MPP+ was demonstrated. Thus, IGF-II is a potential therapeutic tool for prevention and treatment of PD patients suffering mild to moderate emotional stress.</dc:description>
      <dc:date>2023-09-15T11:37:16Z</dc:date>
      <dc:date>2023-09-15T11:37:16Z</dc:date>
      <dc:date>2023</dc:date>
      <dc:type>conference output</dc:type>
      <dc:identifier>https://hdl.handle.net/10630/27536</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:relation>11th IBRO World Congress of Neuroscience IBRO 2023</dc:relation>
      <dc:relation>GRANADA</dc:relation>
      <dc:relation>09/09/2023</dc:relation>
      <dc:rights>open access</dc:rights>
   </ow:Publication>
</rdf:RDF>
</metadata></record></GetRecord></OAI-PMH>